Company

Scopus BioPharma Inc.

Headquarters: New York, NY, United States

Employees: 1

CEO: Alan D. Horsager Ph.D.

NASDAQ: SCPS -47.62%

Market Cap

$2.5 Million

USD as of Jan. 1, 2023

Market Cap History

Scopus BioPharma Inc. market capitalization over time

Evolution of Scopus BioPharma Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Scopus BioPharma Inc.

Detailed Description

Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Scopus BioPharma Inc. has the following listings and related stock indices.


Stock: NASDAQ: SCPS wb_incandescent

Details

Headquarters:

420 Lexington Avenue

Suite 300

New York, NY 10170

United States

Phone: 212-479-2513